For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

4677 products · Showing 4201–4220 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure
NIC3Featured

NIC3 is a selective nucleus accumbens-associated protein-1 (NAC1) inhibitor, binds to the conserved Leu-90 of NAC1, prevents its homodimerization, and leads to proteasomal NAC1 degradation. Anti-cancer activity

NIC3
TCMDC-136364Featured

TCMDC-136364 (AKT Kinase Inhibitor) is an Akt kinase inhibitor, selectively inhibits Akt in proliferating cells expressing Trop-2, also potently inhibits P. falciparum multidrug resistant strain Dd2.

TCMDC-136364

Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp.

Olorofim(F-901318)
ZSA-51Featured

ZSA-51 is a potent and orally active STING agonist. ZSA-51 shows anticancer activity. ZSA-51 remodeles immune microenvironment both in tumor and lymph node.

ZSA-51
AGPS-IN-2iFeatured

AGPS-IN-2i is a novel inhibitor of alkylglyceronephosphate synthase (agps), specifically impairing epithelial to mesenchymal transition (emt) by modulating e-cadherin, snail and mmp2 expression levels.

AGPS-IN-2i

Homoalanosine is a substance with herbicidal activity. Homoalanosine has the activity of removing a variety of weeds, but does not damage rice plants.

Homoalanosine

BRS-3 receptor agonist-2 (compound 2) is a potent BRS-3 receptor agonist, with an EC50 of 2.5 nM for mouse BRS-3 receptor.

BRS-3 receptor agonist-2
MyoseverinFeatured

Myoseverin is an inducer of the reversible fission of multinucleated myotubes into mononucleated fragments, affecting the expression of a variety of growth factor, immunomodulatory, extracellular matrix-remodeling, and stress response genes, consistent with the activation of pathways involved in wound healing and tissue regeneration.

Myoseverin

Pax2 inhibitor EG1 (EG1) is a potent, small molecule inhibitor of Pax2 mediated transcription activation, effectively blocks Pax2 activity and DNA binding with Kd of 1.35-1.5 uM; inhibits Pax2 mediated expression with IC50 of 10 uM, and inhibits proliferation of Pax2 positive renal and ovarian cancer cell lines but has little effect on Pax2 negative cancer cells; inhibits embryonic kidney development.

Pax2 inhibitor EG1
Dac590Featured

Dac590 is an orally active FTO inhibitor. Dac590 has a robust antiproliferative effect on AML cells, and induces apoptosis and cell cycle G1 arrest by inhibiting oncogenic FTO signaling. Dac590 significantly inhibits tumor growth and prolongs survival with no observed toxicity in acute myeloid leukemia (AML) xenograft mcie model, and shows a synergistic effect combined with Decitabine (HY-A0004).

Dac590

GSK-A1 is a potent inhibitor of PI4KA. In vitro using HEK-AT1 cells, GSK-A1 had an IC50 of about 3 nM.

PI4KA inhibitor-A1
LM22A-4Featured

A small molecule BDNF mimetic that act as a direct and specific partial agonist of TrkB (EC50=200-500 pM), but not p75.

LM22A-4
TGFβRI-IN-3Featured

TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology.

TGFβRI-IN-3
GNE-6776Featured

GNE-6776 is a novel potent, specific, non-covalent, orally bioavailable USP7 inhibitor with IC50 of 1.34 uM .

GNE-6776

FLT3 ligand-2 is a Ligand for Target Protein for PROTAC. FLT3 ligand-2 can be used to synthesize PROTAC FLT-3 degrader 1 .

FLT3 ligand-2
PF-04455242Featured

PF-04455242 is a potent, selective κ-opioid receptor (KOR) antagonist with Ki of 3 nM/21 nM/22 nM for hKOR/rKOR/mKOR, respectively.

PF-04455242
GSK717Featured

GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells.

GSK717
HDAC8-IN-20aFeatured

HDAC8-IN-20a is a potent, selective HDAC8 inhibitor with IC50 of 27 nM.

HDAC8-IN-20a

Onvansertib, also know as NMS-P937, PCM-075 and NMS1286937, is an oral Polo-like kinase 1 (PLK1) inhibitor, a key regulator of cell cycle progression and mitosis. It selectively inhibits PLK1 with a reported half-maximal inhibitory concentration (IC₅₀) of approximately 2 nM, while demonstrating significantly lower activity against other Polo-like kinases (PLK2 and PLK3). Onvansertib has shown potent anti-proliferative effects in various cancer cell lines, particularly in colorectal cancer, acute myeloid leukemia (AML), and prostate cancer models. It induces mitotic arrest, leading to apoptosis in tumor cells. Onvansertib has demonstrated synergistic effects when combined with chemotherapeutics such as irinotecan, 5-fluorouracil (5-FU), and decitabine, enhancing their efficacy in resistant cancers.

Onvansertib fumarate

Page 211 of 234 · Browse all 4677 products

Jump to a product page

Featured literature product: HX1 · DCL0028

HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.

Read full formulation and performance →